Sanofi Consumer Healthcare India Q4 FY26 Results PAT Rs 67.8 Crore Up 35.6 Percent YoY

Wed Apr 29 2026

Sanofi Consumer Healthcare India announced its Q4 FY26 financial results on April 28, 2026, posting a PAT of Rs 67.8 crore a 35.6 percent increase year-on-year, as the Consumer Healthcare and OTC Pharmaceuticals company delivered its January to March 2026 quarter earnings. Investors seeking live stock data, expert analysis, and research on Sanofi Consumer Healthcare India Q4 FY26 results can track the stock at Sanofi Consumer Healthcare India on Univest.

Table of Contents

Sanofi Consumer Healthcare India Q4 FY26 Financial Highlights

Sanofi Consumer Healthcare India reported Q4 FY26 PAT of Rs 67.8 crore, a 35.6 percent year-on-year increase from Rs 50 crore in Q4 FY25. The company’s portfolio of OTC and self-care products including Combiflam, Allegra, and Avil drove the strong performance.

Metric	Q4 FY26	Q4 FY25	Change
Revenue / Total Income	approximately Rs 450 crore	Refer NSE filing	Grew (year-on-year growth)
PAT	Rs 67.8 crore	Refer NSE filing	Higher 35.6% YoY
Full Year FY26 PAT	Refer annual filing	Refer filing	As reported
Dividend	Not declared	Refer filing	FY26 final

Sanofi Consumer Healthcare India Q4 FY26 Performance Analysis

Sanofi Consumer Healthcare India’s OTC portfolio delivered strong sell-through in Q4 FY26, aided by seasonal allergy and pain relief product demand. The company has been investing in brand building and modern trade expansion.

Margin expansion in Q4 FY26 for Sanofi Consumer Healthcare India was driven by improved product mix towards higher-margin OTC brands, cost efficiencies in the supply chain, and operating leverage on a growing revenue base.

Also Read: How to Invest Via Univest

Full Year FY26 Business Summary

Management Outlook and FY27 Priorities

Conclusion

Sanofi Consumer Healthcare India Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter with PAT of Rs 67.8 crore. The Consumer Healthcare and OTC Pharmaceuticals company’s results are an important input for investors tracking the earnings season. Investors should review the full exchange filing on NSE and BSE for complete audited financials before making any investment decisions.

This article is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decisions. Past performance is not indicative of future results.

Frequently Asked Questions FAQs

What was Sanofi Consumer Healthcare India Q4 FY26 PAT?

Sanofi Consumer Healthcare India reported Q4 FY26 PAT of Rs 67.8 crore, higher year-on-year. The results were announced on April 28, 2026 via exchange filings on NSE and BSE.

What was Sanofi Consumer Healthcare India revenue in Q4 FY26?

Sanofi Consumer Healthcare India reported Q4 FY26 revenue of approximately Rs 450 crore (year-on-year growth). Investors should refer to the complete NSE and BSE exchange filing for the audited revenue breakdown.

Did Sanofi Consumer Healthcare India declare a dividend for FY26?

As per available information, Sanofi Consumer Healthcare India has not declared a dividend for FY26 in the Q4 results announcement. Refer to the official exchange filing for the latest update.

How did Sanofi Consumer Healthcare India perform in FY26 overall?

FY26 was a growth year for Sanofi Consumer Healthcare India as the self-medication trend accelerated and the company invested in digital marketing, modern trade placement, and pharmacy chain partnerships to expand brand visibility…. Investors can track the complete annual performance metrics in the company’s FY26 annual report and exchange filings.

What is the outlook for Sanofi Consumer Healthcare India in FY27?

Sanofi Consumer Healthcare India’s FY27 strategy focuses on brand penetration in tier-2 and tier-3 markets, expansion of its e-pharmacy presence, and potential new OTC product launches in the digestive health and immunity categories.. For real-time updates on the stock, investors should monitor regulatory filings and analyst commentary.

Where can I track Sanofi Consumer Healthcare India stock and results?

Investors can track Sanofi Consumer Healthcare India (NSE: SANOFICO) share price, financial results, and analyst data on NSE India, BSE India, and financial platforms. The Q4 FY26 results were filed on April 28, 2026.

What sector does Sanofi Consumer Healthcare India operate in?

Sanofi Consumer Healthcare India operates in the Consumer Healthcare and OTC Pharmaceuticals sector in India. The company is listed on both NSE and BSE. Investors should review the company’s business model, competitive positioning, and risk factors before making any investment decision.

Is Sanofi Consumer Healthcare India a good investment after Q4 FY26 results?

Whether Sanofi Consumer Healthcare India is a good investment depends on your individual financial goals, risk tolerance, and investment horizon. The Q4 FY26 results provide one data point about the company’s performance. Please consult a SEBI registered financial advisor before making any investment decision.